276
|
Li G, Fan RM, Chen JL, Wang CM, Zeng YC, Han C, Jiao S, Xia XP, Chen W, Yao ST. Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. Clin Exp Immunol 2014; 175:285-95. [PMID: 24117111 DOI: 10.1111/cei.12220] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2013] [Indexed: 01/14/2023] Open
Abstract
Intracerebral haemorrhage (ICH) is a subtype of stroke that associated with neurological dysfunction and inflammation, which may be ameliorated by a neuroprotective strategy targeting the complement cascade. The protective effect of C5a-receptor antagonist (PMX53) solely and in combination with thrombin antagonist (argatroban) was investigated in the ICH mouse model, respectively. Adult male C57BL/6J wild-type (WT) mice and C3(-/-) mice were randomized to receive PMX53/argatroban 1, 3 and 5 days after ICH. A double injection technique was used to infuse 25 μl of autologous whole blood into the right striatum. Mice in the sham group received only needle insertion. Brain water content and mRNA of inflammatory factors were measured on the first, third and fifth days after ICH, respectively. Neurological dysfunction was assessed using a 28-point neurological scoring system in the three cohorts, namely, on days 1, 3 and 5 following ICH. Animals treated with PMX53/argatroban demonstrated significant improvements in neurological function and fewer neurological apoptosis detected by TUNEL [terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labelling] and βIII-tubulin dual-staining compared with vehicle-treated animals. Compared with sham-treated mice, the brain water content in argatroban/PMX53-treated mice was decreased significantly in both the ipsilateral cortex and ipsilateral striatum. Administration of PMX53/argatroban provided a synergistic neuroprotective effect via reducing inflammatory factors and brain oedema, leading to improvements in neurofunctional outcome. The results of this study indicated that simultaneous blockade of the thrombin and C5a receptors represent a promising neuroprotective strategy in haemorrhagic stroke.
Collapse
|
277
|
Westhovens R, Weinblatt M, Han C, Kim L, Mack M, Lu J, Baker D, Mendelsohn A, Bingham C. FRI0266 Health-Related Quality of Life of Patients with Rheumatoid Arthritis Achieving DAS28 Remission, Improvement in Physical Function and NO Radiographic Progression after Treatment with Intravenous Golimumab. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3819] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
278
|
Chi Z, Li R, qiu R, cao Y, Han C. SU-E-T-39: Analyses of Plan Quality Using Different Gantry Rotation Time On Volumetric Modulated Arc Therapy in Rectal Carcinoma. Med Phys 2014. [DOI: 10.1118/1.4888369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
279
|
Li R, cao Y, Shang K, Wang J, Zhang R, Jing Z, Han C, Chi Z. SU-E-T-643: A Comparison of the DTA and Gamma Index Analysis for IMRT/VMAT Plans in Rectal Carcinoma. Med Phys 2014. [DOI: 10.1118/1.4888979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
280
|
Han C, Keystone E, Fleischmann R, Smolen J, Matteson E, Emery P, Genovese M, Gathany T, Hsia E. THU0156 Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
281
|
Han C, Young SL. Drought and Grazing Disturbances and Resistance to Invasion by Warm- and Cool-Season Perennial Grassland Communities. ECOL RESTOR 2014. [DOI: 10.3368/er.32.1.28] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
282
|
Jin X, Yi J, Zhou Y, Yan H, Han C, Xie C. A new plan quality index for nasopharyngeal cancer SIB IMRT. Phys Med 2014; 30:122-7. [DOI: 10.1016/j.ejmp.2013.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2012] [Revised: 03/20/2013] [Accepted: 03/25/2013] [Indexed: 11/29/2022] Open
|
283
|
Smolen JS, Kay J, Landewé R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Han C, Gathany T, Xu S, Zhou Y, Hsia EC, Doyle MK. THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.730] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
284
|
van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany T, Han C, Inman R. OP0170 Achieving ASDAS-CRP major improvement and inactive disease in patients with ankylosing spondylitis after treatment with golimumab is associated with normalized health related quality of life: Two-year results from the go-raise trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.1853] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
285
|
Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Han C, Gathany T, Zhou Y, Xu S, Hsia EC. FRI0178 Five-year safety and efficacy of golimumab in methotrexate-naïve patients with rheumatoid arthritis: final study results of the phase 3, randomized, placebo-controlled go-before trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.1305] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
286
|
Han C, Kavanaugh A, Genovese MC, Deodhar A, Hsu B, Hsia E. THU0513 Sustained Improvement in Health Related Quality of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated with Golimumab:5yr Results. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.1041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
287
|
Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes I, Ritchlin C, Li S, Wang Y, Zhao N, Ganguly R, Song M, Han C. SAT0264 Ustekinumab Improves Physical Function, Quality of Life and Work Productivity of Patients With Active Psoriatic Arthritis who were NaÏVe To MTX, Despite MTX Therapy or Previously Treated with Anti-Tnfॅ: Results from Psummit I and Psummit II. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.1989] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
288
|
Keystone E, Genovese MC, Hall S, Miranda PC, Bae SC, Han C, Gathany T, Zhou Y, Xu S, Hsia EC. AB0267 Five-year safety and efficacy of golimumab in patients with active rheumatoid arthritis despite prior treatment with methotrexate: final study results of the phase 3, randomized placebo-controlled go-forward trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.2589] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
289
|
Bao C, Huang F, Khan MA, Fei K, Wu Z, Zhuang Y, Gathany T, Han C, Hsia EC. AB0513 Safety and efficacy of golimumab, a human anti-tnf monoclonal antibody injected subcutaneously every 4 weeks, in chinese patients with active ankylosing spondylitis: one-year results of a phase 3, randomized, placebo-controlled study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.2835] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
290
|
Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC. FRI0211 Safety and efficacy of subcutaneous golimumab in chinese patients with active rheumatoid arthritis despite mtx therapy: results from a randomized, placebo-controlled, phase 3 trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.1338] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
291
|
Emery P, Keystone E, Fleischmann R, Genovese M, Klareskog L, Xu S, Han C, Hsia E. AB0486 New, provisional american college of rheumatology and european league against rheumatism remission criteria: Results from 2 randomized, controlled golimumab trials in patients with rheumatoid arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
292
|
Rahman P, Puig L, Gottlieb A, Kavanaugh A, McInnes I, Ritchlin C, Mendelsohn A, Han C. L’ustekinumab améliore les capacités physiques, la qualité de vie globale et celle liée aux problèmes articulaires et cutanés ainsi que la productivité au travail chez des patients présentant une arthrite psoriasique active. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
293
|
Si W, Zhu YY, Li Y, Gao P, Han C, You JH, Linghu RX, Jiao SC, Yang JL. Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer. Braz J Med Biol Res 2013; 46:1074-1081. [PMID: 24345917 PMCID: PMC3935280 DOI: 10.1590/1414-431x20133168] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2013] [Accepted: 08/21/2013] [Indexed: 12/03/2022] Open
Abstract
Our objective was to investigate the efficacy and safety of capecitabine maintenance therapy (CMT) after capecitabine-based combination chemotherapy in patients with metastatic breast cancer. The clinical data of 139 metastatic breast cancer patients treated from March 2008 to May 2012 with capecitabine-based combination chemotherapy were retrospectively analyzed. When initial disease control was achieved by the combination chemotherapy, we used CMT for 50 patients, while 37 patients were treated with a different (non-CMT) maintenance therapy. We compared time to progression (TTP), objective response rate, disease control rate, clinical benefit rate, and safety of the two groups, and a sub-group analysis was performed according to pathological characteristics. Sixty-four percent of the patients received a median of six cycles of a docetaxel+capecitabine combination chemotherapy regimen (range 1-45); the median TTP (MTTP) for the complete treatment was 9.43 months (95%CI=8.38-10.48 months) for the CMT group and 4.5 months (95%CI=4.22-4.78 months; P=0.004) for the non-CMT group. The MTTPs for the maintenance therapies administered after the initial capecitabine combined chemotherapy were 4.11 months (95%CI=3.34-4.87 months) for the CMT group and 2.0 months (95%CI=1.63-2.38 months) for the non-CMT group. Gastrointestinal side effects, decreased white blood cells and palmar-plantar erythrodysesthesia were the main adverse reactions experienced with the combination chemotherapies, CMT and non-CMT treatments. No significant differences in the incidence of adverse reactions were detected in the CMT and non-CMT patients. After initial disease control was achieved with the capecitabine-based combination chemotherapy, CMT can significantly prolong TTP rates with a favorable safety profile.
Collapse
|
294
|
Qiu M, Liu J, Han C, Wu B, Yang Z, Su F, Quan F, Zhang Y. The Influence of Ovarian Stromal/Theca Cells During
In Vitro
Culture on Steroidogenesis, Proliferation and Apoptosis of Granulosa Cells Derived from the Goat Ovary. Reprod Domest Anim 2013; 49:170-6. [DOI: 10.1111/rda.12256] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2013] [Accepted: 10/13/2013] [Indexed: 11/29/2022]
|
295
|
Han C, Dai SF, Liu DC, Pu ZJ, Wei YM, Zheng YL, Wen DJ, Zhao L, Yan ZH. TaALMT1 promoter sequence compositions, acid tolerance, and Al tolerance in wheat cultivars and landraces from Sichuan in China. GENETICS AND MOLECULAR RESEARCH 2013; 12:5602-16. [PMID: 24301929 DOI: 10.4238/2013.november.18.9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Previous genetic studies on wheat from various sources have indicated that aluminum (Al) tolerance may have originated independently in USA, Brazil, and China. Here, TaALMT1 promoter sequences of 92 landraces and cultivars from Sichuan, China, were sequenced. Five promoter types (I', II, III, IV, and V) were observed in 39 cultivars, and only three promoter types (I, II, and III) were observed in 53 landraces. Among the wheat collections worldwide, only the Chinese Spring (CS) landrace native to Sichuan, China, carried the TaALMT1 promoter type III. Besides CS, two other Sichuan-bred landraces and six cultivars with TaALMT1 promoter type III were identified in this study. In the phylogenetic tree constructed based on the TaALMT1 promoter sequences, type III formed a separate branch, which was supported by a high bootstrap value. It is likely that TaALMT1 promoter type III originated from Sichuan-bred wheat landraces of China. In addition, the landraces with promoter type I showed the lowest Al tolerance among all landraces and cultivars. Furthermore, the cultivars with promoter type IV showed better Al tolerance than landraces with promoter type II. A comparison of acid tolerance and Al tolerance between cultivars and landraces showed that the landraces had better acid tolerance than the cultivars, whereas the cultivars showed better Al tolerance than the landraces. Moreover, significant difference in Al tolerance was also observed between the cultivars raised by the National Ministry of Agriculture and by Sichuan Province. Among the landraces from different regions, those from the East showed better acid tolerance and Al tolerance than those from the South and West of Sichuan. Additional Al-tolerant and acid-tolerant wheat lines were also identified.
Collapse
|
296
|
Harms HJ, Nesterov SV, Han C, Danad I, Leonora R, Raijmakers PG, Lammertsma AA, Knuuti J, Knaapen P. Comparison of clinical non-commercial tools for automated quantification of myocardial blood flow using oxygen-15-labelled water PET/CT. Eur Heart J Cardiovasc Imaging 2013; 15:431-41. [DOI: 10.1093/ehjci/jet177] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
297
|
Han C, Wang L, Zhu S, Tian H, Dang R, Kong J. The Application Value Study of Diffusion-Weighted Magnetic Resonance Imaging(DWI) in Target Volume Determination of Esophageal Carcinoma Treatment Using 3DCRT or IMRT. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
298
|
Wang L, Han C, Zhu S, Tian H, Dang R, Kong J. Investigation of Using Diffusion-Weighted Magnetic Resonance Imaging (DWI) to Evaluate the Therapeutic Effect and Prognosis of Esophageal Carcinoma Treatment Using 3DCRT. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
299
|
Seo HJ, Lee BC, Seok JH, Jeon HJ, Paik JW, Kim W, Kwak KP, Han C, Lee KU, Pae CU. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features. PHARMACOPSYCHIATRY 2013; 46:221-6. [PMID: 23963965 DOI: 10.1055/s-0033-1353171] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The present study aimed at investigating the effectiveness and tolerability of -bupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF).51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression-Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment.The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%).Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.
Collapse
|
300
|
Ellis MP, Foden N, Han C, Almeyda R. Improved visualisation of blood while wearing KTP laser protective eyewear using digital manipulation of endoscopic images: seventeen surgeons experience on simulation testing. Clin Otolaryngol 2013; 38:438-42. [PMID: 23731709 DOI: 10.1111/coa.12136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/26/2013] [Indexed: 11/30/2022]
|